BAY-1816032 manufacturers
- BAY-1816032
-
- $32.00
-
2026-07-14
- CAS:1891087-61-8
- Purity: 99.81%
- Supply Ability: 10g
- BAY-1816032
-
- $32.00
-
2026-07-14
- CAS:1891087-61-8
- Purity: 99.81%
- Supply Ability: 10g
|
| | BAY-1816032 Basic information |
| Product Name: | BAY-1816032 | | Synonyms: | BAY-1816032
(BAY1816032);BAY-1816032;Ethanol, 2-[3,5-difluoro-4-[[3-[5-methoxy-4-[(3-methoxy-4-pyridinyl)amino]-2-pyrimidinyl]-1H-indazol-1-yl]methyl]phenoxy]-;2-[3,5-Difluoro-4-[[3-[5-methoxy-4-[(3-methoxy-4-pyridinyl)amino]-2-pyrimidinyl]-1H-indazol-1-yl]methyl]phenoxy]ethanol;inhibit,BAY1816032,Inhibitor,BAY 1816032,BAY-1816032;2-(3,5-Difluoro-4-((3-(5-methoxy-4-((3-methoxypyridin-4-yl)amino)pyrimidin-2-yl)-1H-indazol-1-yl)methyl)phenoxy)ethan-1-ol;BAY-1816032, 10 mM in DMSO | | CAS: | 1891087-61-8 | | MF: | C27H24F2N6O4 | | MW: | 534.51 | | EINECS: | | | Product Categories: | API | | Mol File: | 1891087-61-8.mol |  |
| | BAY-1816032 Chemical Properties |
| Boiling point | 640.8±55.0 °C(Predicted) | | density | 1.40±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO:37.5(Max Conc. mg/mL);70.16(Max Conc. mM) | | form | A solid | | pka | 14.05±0.10(Predicted) | | color | Off-white to yellow |
| WGK Germany | WGK 3 | | Storage Class | 11 - Combustible Solids |
| | BAY-1816032 Usage And Synthesis |
| Uses | BAY-1816032 is a potent and oral available BUB1 (budding uninhibited by benzimidazoles 1) kinase inhibitor with an IC50 of 7 nM. | | Biological Activity | BAY 1816032 is an orally active, ATP-competitive (Ki = 1.2 μM), highly potent and selective BUB1 inhibitor (IC50 = 6.1 nM with 10 μM ATP; affinity Kd = 3.3 nM/BUB1 vs 57 nM/STK10, 850 nM/DMPK2, 2.3 μM/DDR1 and >2.3 μM toward more than 390 other kinases) th at effectively targets BUB1-dependent cellular signaling (H2A-pThr120 IC50 = 29 nM post 1h treatment of nocodazole-arrested HeLa cells) and tumor cell proliferation in vitro (IC50 range from 0.5 to 5.8 μM in 43 human and mouse cancer cultures) and in human triple-negative breast xenograft models in vivo (25-50 mg/kg twice daily p.o.; SUM-149 and MDA-MB-436). | | in vivo | In tumor xenograft studies BAY 1816032 only marginally inhibits tumor growth as single agent upon oral administration, however, upon combination with paclitaxel or docetaxel a strong and statistically significant reduction of tumor size as compared to the respective monotherapy is observed[1]. | | storage | Store at -20°C | | References | [1] Siemeister G, et al. BAY 1816032, a novel BUB1 kinase inhibitor with potent antitumor activity [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Ishington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 287. doi:10.1158/1538-7445.AM2017-287 |
| | BAY-1816032 Preparation Products And Raw materials |
|